

Living Well with Lung Cancer

Submission date 12/05/2010	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 12/05/2010	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 29/03/2022	Condition category Cancer	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol

<http://www.cancerhelp.org.uk/trials/a-study-of-follow-up-care-after-treatment-for-lung-cancer>

Contact information

Type(s)

Scientific

Contact name

Dr Lynn Calman

Contact details

MRC Research Fellow
School of Nursing, Midwifery and Social Work
The University of Manchester
Jean McFarlane Building
University Place
Oxford Road
Manchester
United Kingdom
M13 9PL

Additional identifiers

Protocol serial number

6073; MRC G0601695

Study information

Scientific Title

Living well with lung cancer: evaluating the effectiveness of a sustainable model of follow-up care

Study objectives

Aims:

1. To develop a sustainable model of follow-up service delivery
2. To determine if the model is potentially beneficial (proof of concept) through an exploratory (feasibility) trial with outcomes focused on quality of life, patient satisfaction and cost effectiveness

Ethics approval required

Old ethics approval format

Ethics approval(s)

South Manchester Research Ethics Committee, 24/06/2009, ref: 09/H1003/72

Primary study design

Observational

Study design

Multicentre observational process of care qualitative study

Study type(s)

Quality of life

Health condition(s) or problem(s) studied

Topic: National Cancer Research Network; Subtopic: Lung Cancer; Disease: Lung (small cell), Lung (non-small cell)

Interventions

Stage one: developing the intervention -

In order to develop a robust evidence based intervention this project is designed using steps of the MRC framework for developing and evaluating complex interventions (MRC 2000/2007). The first stage of this framework is to develop the intervention using primarily qualitative methods, once the intervention has been developed a feasibility trial will be designed.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

1. Quality of life
2. Symptom control
3. Patient satisfaction

Key secondary outcome(s)

1. Survival
2. Economic evaluation

Completion date

30/04/2011

Eligibility

Key inclusion criteria

1. Completed initial treatment for lung cancer
2. Suitable for nurse-led follow-up (as defined in Stage 1)
3. Physically and psychologically able and willing to complete outcome measures
4. Not taking part in any other clinical trial
5. Age restrictions will not be imposed, both male and female participants will be recruited

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

31

Key exclusion criteria

Patients with a diagnosis of mesothelioma will be excluded at this stage due to complexities of disease management.

Date of first enrolment

01/11/2009

Date of final enrolment

30/04/2011

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

MRC Research Fellow

Manchester

United Kingdom

M13 9PL

Sponsor information

Organisation

University of Manchester (UK)

ROR

<https://ror.org/027m9bs27>

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (MRC) (UK) (ref: G0601695)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Plain English results		08/01/2014	29/03/2022	No	Yes